| answer text |
<p>Information on National Institute for Health and Care Excellence (NICE) technology
appraisal recommendations relating to cancer treatments published in 2012, 2013, and
2014, including the estimated size of the eligible patient population and the applicability
of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE
has advised that it publishes a list on its website that includes information on its
technology appraisal decisions on cancer treatments. The list, which is updated monthly,
includes each appraisal number, year of publication, the appraisal process used, name
ofthe technology, the disease or condition for which it has been appraised, the recommendation
category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p>
</p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold
in its appraisals, but uses a range that allows other factors to be taken into account
in deciding whether to recommend a treatment. We are advised that the most likely
cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is
published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's
key conclusions' table within section four of each appraisal's final technology appraisal
guidance documents. The same section of this document also sets out whether a treatment
was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p>
</p>
|
|
